Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Endometrial Cancer
NCT05691010Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in endometrial cancer (EC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Feasibility of integrated delivery of short-course IMRT with carboplatin/paclitaxel at 3 years. Started Jan 2023; status: recruiting.
02
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05691010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691010.